VivoSeq
Other

Excessive Sleepiness

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Excessive Sleepiness is an early-stage landscape with 0 programs across 2 companies. The most active players are Jazz Pharmaceuticals, Vanda Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Jazz Pharmaceuticals logo

Jazz Pharmaceuticals

0 programs

PreclinicalV

Vanda Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

11

clinical trials

Completed10 · 91%
Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD
Completed·CCephalon·Phase 3·NCT00080288·254 enrolled
"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT02348619·174 enrolled
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 3·NCT02348606·476 enrolled
Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness
Completed·CCephalon·Phase 3·NCT00228553·743 enrolled
Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT02806895·34 enrolled
Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness
Completed·CCephalon·Phase 3·NCT00214968·92 enrolled
VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive Sleepiness
Completed·VVanda Pharmaceuticals·Phase 2·NCT00467441·60 enrolled
Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder
Completed·CCephalon·Phase 4·NCT01080807·385 enrolled
Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder
Completed·CCephalon·Phase 3·NCT00758498·427 enrolled
A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Completed·Jazz Pharmaceuticals logoJazz Pharmaceuticals·Phase 2·NCT03037203·66 enrolled
Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder
Terminated·—·Phase 4·NCT04788953·84 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)